Your browser doesn't support javascript.
AVIFAVIR for Treatment of Patients With Moderate Coronavirus Disease 2019 (COVID-19): Interim Results of a Phase II/III Multicenter Randomized Clinical Trial.
Ivashchenko, Andrey A; Dmitriev, Kirill A; Vostokova, Natalia V; Azarova, Valeria N; Blinow, Andrew A; Egorova, Alina N; Gordeev, Ivan G; Ilin, Alexey P; Karapetian, Ruben N; Kravchenko, Dmitry V; Lomakin, Nikita V; Merkulova, Elena A; Papazova, Natalia A; Pavlikova, Elena P; Savchuk, Nikolay P; Simakina, Elena N; Sitdekov, Tagir A; Smolyarchuk, Elena A; Tikhomolova, Elena G; Yakubova, Elena V; Ivachtchenko, Alexandre V.
  • Ivashchenko AA; ChemRar High-Tech Center, Khimki, Moscow region, Russian Federation.
  • Dmitriev KA; Russian Direct Investment Fund, Moscow, Russian Federation.
  • Vostokova NV; IPHARMA LLC, Skolkovo Innovative Centre, Moscow, Russian Federation.
  • Azarova VN; IPHARMA LLC, Skolkovo Innovative Centre, Moscow, Russian Federation.
  • Blinow AA; Chromis LLC, Skolkovo Innovative Centre, Moscow, Russian Federation.
  • Egorova AN; IPHARMA LLC, Skolkovo Innovative Centre, Moscow, Russian Federation.
  • Gordeev IG; City Clinical Hospital n.a. O.M. Filatov, Moscow, Russian Federation.
  • Ilin AP; Department of Chemistry and Technology, Chemical Diversity Research Institute, Khimki, Moscow region, Russian Federation.
  • Karapetian RN; Department of Biology, Chemical Diversity Research Institute, Khimki, Moscow region, Russian Federation.
  • Kravchenko DV; Department of Chemistry and Technology, Chemical Diversity Research Institute, Khimki, Moscow region, Russian Federation.
  • Lomakin NV; Central Clinical Hospital with Polyclinic, Moscow, Russian Federation.
  • Merkulova EA; IPHARMA LLC, Skolkovo Innovative Centre, Moscow, Russian Federation.
  • Papazova NA; Department of Finished Dosage Forms, Chemical Diversity Research Institute, Khimki, Moscow region, Russian Federation.
  • Pavlikova EP; Moscow State University n.a. M. V. Lomonosov, Moscow, Russian Federation.
  • Savchuk NP; Chemical Diversity Research Institute, Khimki, Moscow region, Russian Federation.
  • Simakina EN; Clinical Hospital No.1, Smolensk, Russian Federation.
  • Sitdekov TA; Russian Direct Investment Fund, Moscow, Russian Federation.
  • Smolyarchuk EA; First Moscow State Medical University n.a. I.M. Sechenov, Moscow, Russian Federation.
  • Tikhomolova EG; Infectious clinical hospital No. 2, Nizhny Novgorod, Russian Federation.
  • Yakubova EV; Chromis LLC, Skolkovo Innovative Centre, Moscow, Russian Federation.
  • Ivachtchenko AV; Chemical Diversity Research Institute, Khimki, Moscow region, Russian Federation.
Clin Infect Dis ; 73(3): 531-534, 2021 08 02.
Article in English | MEDLINE | ID: covidwho-1338663
ABSTRACT
In May 2020 the Russian Ministry of Health granted fast-track marketing authorization to RNA polymerase inhibitor AVIFAVIR (favipiravir) for the treatment of COVID-19 patients. In the pilot stage of Phase II/III clinical trial, AVIFAVIR enabled SARS-CoV-2 viral clearance in 62.5% of patients within 4 days, and was safe and well-tolerated. Clinical Trials Registration. NCT04434248.
Subject(s)
Keywords
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 Type of study: Experimental Studies / Prognostic study / Randomized controlled trials Limits: Humans Language: English Journal: Clin Infect Dis Journal subject: Communicable Diseases Year: 2021 Document Type: Article

Similar

MEDLINE
LILACS
LIS
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 Type of study: Experimental Studies / Prognostic study / Randomized controlled trials Limits: Humans Language: English Journal: Clin Infect Dis Journal subject: Communicable Diseases Year: 2021 Document Type: Article